Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cytodyn stock price plummeted violently today , incredible ...what next? Do you think the same trend continue?
Heavy volume, SP spike ..$12 next
Explosive move in SP will happen in weeks! Increase in Rubraca sale expected.
CLVS Epic price tomorrow ...SP will reach new high ...good luck everyone!
I guess Some news pending ...probably revenue
American Medicine discussing leronlimab - live show
#Leronlimab is an artificial antibody that works against the 2nd phase of #COVID19. Joining to discuss this potential treatment is #MichaelDaugherty, Pres. of #LabMD. Listen Saturday @NewsRadio710 8AM, @wbhpam 10AM, @WFLANews 12PM & 6PM, @NewsTalk931 12PM & Sunday @1055WERC 1PM! pic.twitter.com/uqqKOTUZId
— American Medicine Today (@AmericanMed2day) August 25, 2020
Leronlimab mentioned again by Dr. Janette Nesheiwat - 3:50 mark
https://finance.yahoo.com/video/containing-coronavirus-college-students-done-204231329.html
(@NBSaphierMD 6h
Will tonight’s presser go a step further and discuss monoclonal Ab treatment Leronlimab? Stay tuned.)
https://twitter.com/NBSaphierMD/status/1297612963256446977
Short traders may unleash an price attack tomorrow if no efficacy results from NP.
CYDY at the top of the list!
https://finance.yahoo.com/news/10-best-worst-performing-biotechs-221832715.html
Big day coming! Many millionaires born in few weeks!
Covid result will be available Only after share holder meeting. (After July 22nd)
I guess we may need to wait bit long for new HIV BLA filing now.
Oh god, short may taker over. The price probably drop.
Recently Several retail groups and their students shorted this stock heavily, pretty much coordinated fashion - unbelievable.
Anything can happen at FDA ...we don’t know the result ..50-50 chance.
Any news for cydy today? Look like stock going down!
A conditional buyout offer from BP available depending on the trial result.
I heated trump administration is going to announce tocilizumab as therapeutic for covid 19
Latest: Yale talk about leronlimab
Yes phase 3 enrollment complete however big news yet to come - 62 days more.
https://seekingalpha.com/news/3582091-clovis-completes-enrollment-in-study-of-rubraca-combo-in-ovarian-cancer
Seem rumor- but with CLVS and EXEL merger.
interesting, possible merger news active...seems more sense now..
Doesn’t matter what NP says ...CYDY good news coming soon. Many things going in parallel.
Yes, Distribution agreement signed (Non Binding) with more than 3 or 5 agencies. Exciting times for Cytodyn ..BLA PDUFA coming soon....latest interview here
I think so, they are already in the process of uplisting CYDY to NYSE
What PR ? Status on HIV PDUFA?
I guess Sanofi may offer a buyout plan - I heard some news early March ...so let’s see.
Excellent..CYDY already trading 9% up at German exchange , $3:32 USD
In Euro link
https://www.bloomberg.com/quote/CYDY:GR
Wow...so the results looks amazing!!
Montefiore update on CYDY
#cytokinestorms have inflamed & damaged the organs of many #COVID19 patients. In two separate trials, Montefiore & @EinsteinMed were the first site to investigate anti-inflammatory drug leronlimab’s ability to prevent these storms: https://t.co/rrVdeV0aLe pic.twitter.com/pSTcZNuoEJ
— Montefiore Health System (@MontefioreNYC) May 21, 2020
Government Grant Approval!!- I heard someone from other forum mentioning about some sort of government grant approval - not sure if it is accurate.
I think a BIG material event to announce along with follow up PR on Tuesday.
Probably a life changing event for CYDY.
My guess is some PR may come out on compassionate use approval - very big news!
Some update on related to CYDY NASDAQ uplisting.
All, I guess CYDY uplisting to NASDAQ!
Yes, we’re heading to $15-16 range. More long term investors are entering to the scene.